Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Summit Therapeutics (SMMT) EBIT Margin: 2016-2024

Historic EBIT Margin for Summit Therapeutics (SMMT) over the last 3 years, with Dec 2024 value amounting to 729,044.44%.

  • Summit Therapeutics' EBIT Margin was N/A to 729,044.44% in Q4 2024 from the same period last year, while for Dec 2024 it was 2,080.29%, marking a year-over-year change of. This contributed to the annual value of 2,601.87% for FY2024, which is 134154.00% down from last year.
  • Per Summit Therapeutics' latest filing, its EBIT Margin stood at 729,044.44% for Q4 2024, which was up 30,546.39% from 2,378.89% recorded in Q3 2024.
  • Summit Therapeutics' 5-year EBIT Margin high stood at 729,044.44% for Q4 2024, and its period low was -7,700.00% during Q3 2022.
  • In the last 2 years, Summit Therapeutics' EBIT Margin had a median value of 2,378.89% in 2024 and averaged 241,241.11%.
  • Data for Summit Therapeutics' EBIT Margin shows a maximum YoY slumped of 71,348bps (in 2020) over the last 5 years.
  • Over the past 3 years, Summit Therapeutics' EBIT Margin (Quarterly) stood at -2,343.08% in 2020, then followed by -7,700.00% in 2022, then followed by 729,044.44% in 2024.
  • Its EBIT Margin was 729,044.44% in Q4 2024, compared to 2,378.89% in Q3 2024 and -7,700.00% in Q3 2022.